Argenx SE 6-K, filed Feb 27, 2020
Argenx SE (ARGX)
About this 6-K
Argenx SE filed this 6-K on February 27, 2020.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF1934
For the Month of February 2020
Commission File Number: 001-38097
ARGENX SE
(Translation of registrant’s name into English)
Willemstraat 54811 AH, Breda, the Netherlands
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
argenx SE
On February 27, 2020, argenx SE (the “Company”) issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
The information contained in this Current Report on Form 6-K,including Exhibit 99.1, is incorporated by reference into the Company’s Registration Statements on Forms F-3 (File No. 333-225370)and S-8 (File No. 333-225375).
| Exhibit | Description |
|---|---|
| 99.1 | Press Release dated February 27, 2020 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| ARGENX SE | ||
|---|---|---|
| Date: February 27, 2020 | By: | /s/ Dirk Beeusaert |
| Dirk Beeusaert | ||
| General Counsel |
Exhibit 99.1
argenx reports full year 2019financial results and provides fourth quarter business update
Topline data from Phase 3 ADAPT trial of efgartigimod in gMG expected in mid-2020
Continued progress across broadest FcRn antagonist pipeline with up to five Phase 3 trials to be ongoing in 2020
- Ended 2019 well-capitalized to advance late-stage pipeline with €1.3 billion in cash, cash equivalents and current financial assets
February 27, 2020
Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced its financial results for the full year 2019 and provided a fourth quarter business update and outlook for 2020.
“The significant achievements we made throughout 2019 have provided the foundation for us to execute yet another exciting year ahead as we advance our ‘argenx 2021’ vision to become a global, integrated immunology company,” commented Tim Van Hauwermeiren, CEO of argenx. “We are progressing our entire FcRn pipeline across four indications with a fifth to be announced this year and are planning for a 2021 launch of efgartigimod in gMG, which could be the first approved FcRn antagonist.”
“We continue to build innovation into every step of our development, highlighted by our collaborative Innovative Access Program translating immunology breakthroughs into medicines, our unique trial designs incorporating input from our patients, and our integrated commercial thinking with the launch of the first real-world evidence study in MG. We have demonstrated our ability to perform across our late-stage pipeline and will prioritize maintaining this reputation for execution in 2020 with up to five registrational trials to be ongoing.”
FOURTH QUARTER 2019 AND RECENT HIGHLIGHTS
argenx continues to execute on its “argenx 2021” vision to become a fully integrated, global immunology company, which includes the building of two initial commercial franchises in neuromuscular disorders and hematology/oncology and the expanding of its global presence to support its anticipated first commercial launch of efgartigimod in 2021.
Efgartigimod: First-in-class opportunityacross range of high-value autoimmune indications
Efgartigimod is a human IgG1 Fc fragment engineered for optimal blocking of FcRn and targeted reduction of IgG autoantibodies. argenx expects to have up to five registrational trials ongoing in 2020. Efgartigimod is currently being evaluated in four targeted indications where IgG autoantibodies are directly pathogenic, including:
| · | Generalized Myasthenia Gravis (gMG) |
|---|---|
| · | Completed enrollment of 167 patients in global, multi-center Phase 3 ADAPT trial with 10mg/kg intravenous<br>(IV) efgartigimod. Topline results from ADAPT expected in mid-2020 |
| --- | --- |
| · | Received Fast Track designation for efgartigimod in MG from U.S. Food and Drug Administration (FDA) |
| --- | --- |
| · | Biologics License Agreement (BLA) expected to be filed in fourth quarter of 2020 with launch planned<br>for 2021 |
| --- | --- |
| · | Plans to engage with FDA in 2020 on potential bridging strategy for 1000mg subcutaneous (SC) ENHANZE®-efgartigimod |
| --- | --- |
| · | Primary Immune Thrombocytopenia (ITP) |
| --- | --- |
| · | Global Phase 3 registrational program includes: |
| --- | --- |
| · | Ongoing Phase 3 ADVANCE trial evaluating approximately 150 primary ITP patients dosed with 10mg/kg<br>IV efgartigimod for both induction and maintenance of platelet response |
| --- | --- |
| · | ADVANCE SC trial expected to initiate in second half of 2020 evaluating 10mg/kg IV efgartigimod<br>for induction of platelet response and fixed dose of SC efgartigimod for maintenance |
| --- | --- |
| · | Small confirmatory IV trial expected to initiate in first half of 2020 |
| --- | --- |
| · | Presented previously announced data from completed Phase 2 proof-of-concept trial in December 2019<br>at 61^st^ American Society of Hematology (ASH) Annual Meeting demonstrating that efgartigimod was well-tolerated and showed<br>correlation of reduced IgG levels, increased platelet counts and reduced bleeding in ITP patients |
| --- | --- |
| · | Published Phase 2 data in American Journal of Hematology in article titled, “Phase 2 study<br>of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia” |
| --- | --- |
| · | Pemphigus Vulgaris (PV) |
| --- | --- |
| · | Announced positive proof-of-concept data in 23 patients from Phase 2 trial evaluating 10mg/kg and<br>25mg/kg IV efgartigimod, which support advancement to registrational trial anticipated to start in second half of 2020 |
| --- | --- |
| · | 78% (18/23) of patients achieved rapid disease control (DC); median time to DC for both monotherapy<br>and combination therapy is 14-15 days |
| --- | --- |
| · | Fast complete clinical remission (CR) observed within 2-10 weeks of treatment in 70% (5/7) of patients<br>receiving optimized dosing regimen |
| --- | --- |
| · | Established optimized dosing regimen to be weekly or bi-weekly dosing of efgartigimod in combination<br>with oral prednisone (0.25-0.5mg/kg) |
| --- | --- |
| · | Patients still in trial in extended dosing cohort; detailed results of Phase 2 data to be presented<br>during Society for Investigative Dermatology Annual Meeting in May 2020 |
| --- | --- |
| · | Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) |
| --- | --- |
| · | Launched Phase 2 ADHERE trial with SC ENHANZE®-efgartigimod |
| --- | --- |
| · | Fifth<br>efgartigimod indication expected to be announced in 2020 |
| --- | --- |
argenx has established proof-of-concept in all three beachhead indications in neuromuscular disorders, hematology and dermatology therapeutic areas for efgartigimod.
Cusatuzumab: First-in-class opportunitywith potential in hematological malignancies
Cusatuzumab is an anti-CD70 monoclonal antibody being developed under an exclusive global collaboration and license agreement with Janssen for the treatment of acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS) and other hematological malignancies.
| · | Enrollment ongoing in dose-confirming Phase 2 pivotal CULMINATE trial of cusatuzumab in combination with azacitidine for newly<br>diagnosed, elderly AML patients who are unfit for intensive chemotherapy |
|---|---|
| · | Phase 1b platform trial underway in various AML subpopulations and settings with initial trial evaluating combinations of cusatuzumab,<br>venetoclax and azacitidine; additional trials expected to launch under platform trial in first half of 2020 |
| --- | --- |
| · | Randomized Phase 2 trial of cusatuzumab in combination with azacitidine in higher-risk MDS patients expected to launch in first<br>half of 2020 |
| --- | --- |
| · | Phase 1 trial of cusatuzumab in combination with azacitidine to launch in first half 2020 in Japanese patients with AML and<br>MDS |
| --- | --- |
| · | Data update from cusatuzumab development expected in 2020 |
| --- | --- |
ARGX-117: First-in-class anti-C2 antibody expected to enter clinic in first quarter 2020
ARGX-117 is a complement-targeting antibody against C2 with potential therapeutic applications in multiple autoimmune diseases.
| · | Phase 1 trial in healthy volunteers expected to begin in first quarter of 2020 |
|---|---|
| o | Multiple doses and formulations (IV and SC ENHANZE®-efgartigimod) to be evaluated as part of<br>dose-finding work |
| --- | --- |
| o | Following analysis of Phase 1 data in fourth quarter of 2020, argenx plans to launch Phase 2 proof-of-concept<br>trial in multifocal motor neuropathy (MMN) within its neuromuscular franchise and to develop in additional indications |
| --- | --- |
Early-stage Pipeline
argenx continues to expand its early-stage pipeline with first-in-class antibodies against immunologic targets:
| · | Lead optimization work ongoing of ARGX-118 for airway inflammation |
|---|---|
| · | New product candidate ARGX-119 expected to be announced in 2020 |
| --- | --- |
Collaborations
| · | Received first development milestone payment under Janssen collaboration for achievement of enrollment<br>milestone in Phase 2 pivotal CULMINATE trial |
|---|---|
| · | Awarded first clinical milestone payment under AbbVie collaboration for initiating first-in-human<br>clinical trial with antibody product ABBV-151 (formerly named ARGX-115), which was created as part of argenx’s Innovative<br>Access Program and exclusively licensed to AbbVie in 2016 |
| --- | --- |
****
YEAR 2019 FINANCIAL RESULTS (CONSOLIDATED)
| Year Ended December 31, | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| in thousands of € | 2019 | 2018 | Variance | ||||||
| Revenue | € | 69,783 | € | 21,482 | € | 48,301 | |||
| Other operating income | € | 12,801 | € | 7,749 | € | 5,052 | |||
| Total operating income | € | 82,584 | € | 29,231 | € | 53,353 | |||
| Research and development expenses | € | (197,665 | ) | € | (83,609 | ) | € | (114,056 | ) |
| Selling, general and administrative expenses | € | (64,569 | ) | € | (27,471 | ) | € | (37,098 | ) |
| Changes in fair value on financial assets | 1,096 | — | 1,096 | ||||||
| Operating loss | € | (178,554 | ) | € | (81,849 | ) | € | (96,705 | ) |
| Financial income | € | 14,399 | € | 3,694 | € | 10,705 | |||
| Financial expense | € | (124 | ) | € | — | € | (124 | ) | |
| Exchange gain/(losses) | € | 6,066 | € | 12,308 | € | (6,242 | ) | ||
| Loss before taxes | € | (158,213 | ) | € | (65,847 | ) | € | (92,366 | ) |
| Income tax expense | € | (4,752 | ) | € | (794 | ) | € | (3,958 | ) |
| Loss for the year and total comprehensive loss | € | (162,965 | ) | € | (66,641 | ) | € | (96,324 | ) |
| Net increase in cash, cash equivalents and current financial assets compared to year-end 2018 and 2017 | € | 771,252 | € | 204,795 | |||||
| Cash, cash equivalents and current financial assets at the end of the period | € | 1,335,821 | € | 564,569 |
DETAILS OF THE FINANCIAL RESULTS
Cash, cash equivalents and current financial assets totaled €1,335.8 million for the year ended December 31, 2019, compared to €564.6 million for the year ended December 31, 2018. The increase in the year-end cash balance on December 31, 2019 resulted primarily from (i) the closing of the collaboration and license agreement for cusatuzumab with Janssen which resulted in a $300 million upfront payment and a $200 million equity investment in January 2019, and (ii) €479.0 million of net proceeds received from the global offering in November 2019.
Operating income increased by €53.4 million for the year ended December 31, 2019 to €82.6 million, compared to €29.2 million for the year ended December 31, 2018. The increase primarily related to (i) the partial recognition of the upfront payment and the recognition of research and development service fees under the collaboration and license agreement for cusatuzumab with Janssen and (ii) the recognition of the milestone payment following the initiation of a first-in-human clinical trial with ABBV-151 under the AbbVie collaboration.
Research and development expenses totaled €197.7 million and €83.6 million for the years ended December 31, 2019 and 2018, respectively. The increase is mainly the result of (i) increased external research and development expenses reflecting higher clinical trial costs and manufacturing expenses related to the development of argenx’s product candidate portfolio and (ii) higher personnel expenses as a result of increased costs of the share-based payment compensation plans related to the grant of stock options to its research and development employees and increased costs associated with additional research and development employees.
Selling, general and administrative expenses totaled €64.6 million and €27.5 million for the years ended December 31, 2019 and 2018, respectively. The increase of €37.1 million was principally due to an increase of personnel expense, resulting from (i) higher costs of the share-based payment compensation plans related to the grant of stock options to argenx’s selling, general and administrative employees and (ii) increased costs associated with additional employees recruited to strengthen its selling, general and administrative activities, notably in preparation of the potential commercial launch of efgartigimod in the U.S.
For the year ended December 31, 2019, financial income amounted to €14.4 million compared to €3.7 million for the year ended December 31, 2018. The increase of €10.7 million primarily related to an increase in the interest received on argenx’s cash, cash equivalents and current financial assets.
Exchange gains totaled €6.1 million for the year ended December 31, 2019 compared to €12.3 million for the year ended December 31, 2018 and were mainly attributable to unrealized exchange rate gains on argenx’s cash, cash equivalents and current financial assets position in U.S. dollars due to the favorable fluctuation of the EUR/USD exchange rate.
The total comprehensive loss for the year ended December 31, 2019 was €163.0 million compared to €66.6 million for the year ended December 31, 2018.
US SEC and statutory Financial Reporting
argenx’s primary accounting standard for quarterly earnings releases and annual reports is International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB). Quarterly summarized statements of profit and loss based on IFRS as issued by the IASB are available on www.argenx.com.
In addition to reporting financial figures in accordance with IFRS as issued by the IASB, argenx also reports financial figures in accordance with IFRS as adopted by the EU for statutory purposes. The consolidated statement of financial position, the consolidated statements of profit and loss, the consolidated statements of cashflow, and the consolidated statement of changes in equity are not affected by any differences between IFRS as issued by the IASB and IFRS as adopted by the EU.
The consolidated statement of profit and loss data of argenx SE as of December 31, 2019, as presented in this press release is unaudited.
Annual Report 2019
argenx will publish its 2019 Annual Report based on IFRS as issued by the IASB and its 2019 Annual Report for statutory purposes based on IFRS as adopted by the EU on March 24, 2020. These Annual Reports will be available on www.argenx.com.
EXPECTED 2020 FINANCIAL CALENDAR:
| · | May 14 2020: Q1 financial results & business update |
|---|---|
| · | July 30 2020: HY 2020 financial results & business update |
| --- | --- |
| · | October 22 2020: Q3 financial results & business update |
| --- | --- |
CONFERENCE CALL DETAILS
The full year results will be discussed during a conference call and webcast presentation today at 3 pm CET/9 am ET. To participate in the conference call, please select your phone number below and use the confirmation code 2484158. The webcast may be accessed on the homepage of the argenx website at www.argenx.com or by clicking here.
Dial-in numbers:
Please dial in 5–10 minutes priorto 3 pm CET/ 9 am ET using the number and conference ID below.
| Confirmation Code: 2484158 | |
|---|---|
| Belgium | +32 (0)2 400 9874 |
| Belgium | 0800 48740 |
| France | +33 (0)1 767 00794 |
| France | 0805 103028 |
| Netherlands | +31 (0)20 714 3545 |
| Netherlands | 0800 0249557 |
| United Kingdom | +44 (0)844 571 8892 |
| United Kingdom | 0800 376 7922 |
| United States | +1 (631) 510 7495 |
| United States | +1 (866) 966 1396 |
About argenx
argenx is a global immunology company developing antibody-based medicines for patients suffering from severe autoimmune diseases and cancer. By translating immunology breakthroughs into innovative drug candidates, argenx is building a world-class portfolio of first-in-class antibodies in both early and late clinical-stages of development. argenx is evaluating efgartigimod in multiple serious autoimmune indications and cusatuzumab in hematological malignancies in collaboration with Janssen, along with advancing earlier stage assets within its therapeutic franchises.
www.argenx.com
For further information, please contact:
Beth DelGiacco, Vice President, Investor Relations
+1 518 424 4980
bdelgiacco@argenx.com
Joke Comijn, Director Corporate Communications & Investor Relations (EU)
+32 (0)477 77 29 44
+32 (0)9 310 34 19
info@argenx.com
Forward-looking Statements
The contents of this announcement includestatements that are, or may be deemed to be, “forward-looking statements.” These forward-looking statements can beidentified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,”“expects,” “intends,” “may,” “will,” or “should” and include statementsargenx makes concerning its 2020 business and financial calendar and related plans; the clinical data of its product candidates;the intended results of its strategy and argenx’s, and its collaboration partners’, advancement of, and anticipatedclinical development, data readouts and regulatory milestones and plans, including the timing of planned clinical trials and expecteddata readouts. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned thatany such forward-looking statements are not guarantees of future performance. argenx’s actual results may differ materiallyfrom those predicted by the forward-looking statements as a result of various important factors, including argenx’s expectationsregarding its the inherent uncertainties associated with competitive developments, preclinical and clinical trial and product developmentactivities and regulatory approval requirements; argenx’s reliance on collaborations with third parties; estimating the commercialpotential of argenx’s product candidates; argenx’s ability to obtain and maintain protection of intellectual propertyfor its technologies and drugs; argenx’s limited operating history; and argenx’s ability to obtain additional fundingfor operations and to complete the development and commercialization of its product candidates. A further list and descriptionof these risks, uncertainties and other risks can be found in argenx’s U.S. Securities and Exchange Commission (SEC) filingsand reports, including in argenx’s most recent annual report on Form 20-F filed with the SEC as well as subsequent filingsand reports filed by argenx with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on suchforward-looking statements. These forward-looking statements speak only as of the date of publication of this document. argenxundertakes no obligation to publicly update or revise the information in this press release, including any forward-looking statements,except as may be required by law.
ARGENX SE
CONSOLIDATED STATEMENTOF FINANCIAL POSITION
| As of | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| December 31, | |||||||||
| (in thousands of €) | 2019 | 2018 | 2017 | ||||||
| ASSETS | |||||||||
| Current assets | |||||||||
| Cash and cash equivalents | € | 331,282 | € | 281,040 | € | 190,867 | |||
| Restricted cash — current | — | 1,692 | 1,692 | ||||||
| Research and development incentive receivables — current | 261 | 301 | 158 | ||||||
| Financial assets — current | 1,004,539 | 283,529 | 168,907 | ||||||
| Prepaid expenses | 9,022 | 2,995 | 2,338 | ||||||
| Trade and other receivables | 28,115 | 2,886 | 2,842 | ||||||
| Total current assets | 1,373,219 | 572,443 | 366,804 | ||||||
| Non-current assets | |||||||||
| Restricted cash — non-current | 630 | 251 | 256 | ||||||
| Research and development incentive receivables — non-current | 8,566 | 4,883 | 3,033 | ||||||
| Other non-current assets | — | — | 125 | ||||||
| Financial assets — non-current | 2,596 | 1 | 1 | ||||||
| Property, plant and equipment | 8,167 | 824 | 676 | ||||||
| Intangible assets | 40,161 | 56 | 13 | ||||||
| Total non-current assets | 60,120 | 6,015 | 4,104 | ||||||
| TOTAL ASSETS | € | 1,433,339 | € | 578,458 | € | 370,908 | |||
| As of | |||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| December 31, | |||||||||
| (in thousands of €) | 2019 | 2018 | 2017 | ||||||
| EQUITY AND LIABILITIES | |||||||||
| Equity | |||||||||
| Equity attributable to owners of the parent | |||||||||
| Share capital | € | 4,276 | € | 3,597 | € | 3,217 | |||
| Share premium | 1,308,539 | 673,454 | 430,518 | ||||||
| Accumulated losses | (332,568 | ) | (169,603 | ) | (100,568 | ) | |||
| Other reserves | 70,499 | 30,947 | 11,764 | ||||||
| Total equity | € | 1,050,746 | € | 538,395 | € | 344,931 | |||
| Non-current liabilities | 222,636 | 7 | 1,460 | ||||||
| Provisions for employee benefits | 64 | 7 | 25 | ||||||
| Lease liabilities — non-current | 4,540 | — | — | ||||||
| Deferred revenue — non-current | 218,032 | — | 1,435 | ||||||
| Current liabilities | 159,957 | 40,056 | 24,517 | ||||||
| Lease liabilities — current | 1,974 | — | — | ||||||
| Trade and other payables | 85,301 | 37,072 | 15,285 | ||||||
| Tax liabilities | 344 | 823 | 597 | ||||||
| Deferred revenue — current | 72,338 | 2,161 | 8,635 | ||||||
| Total liabilities | € | 382,593 | € | 40,063 | € | 25,977 | |||
| TOTAL EQUITY AND LIABILITIES | € | 1,433,339 | € | 578,458 | € | 370,908 |
ARGENX SE
CONSOLIDATED STATEMENT OF PROFIT AND LOSS AND OTHERCOMPREHENSIVE
INCOME
| (in thousands of except for shares and EPS) | 2018 | 2017 | ||||||
| Revenue | 69,783 | € | 21,482 | € | 36,415 | |||
| Other operating income | 12,801 | 7,749 | 4,841 | |||||
| Total operating income | 82,584 | 29,231 | 41,256 | |||||
| Research and development expenses | (197,665 | ) | (83,609 | ) | (51,740 | ) | ||
| Selling, general and administrative expenses | (64,569 | ) | (27,471 | ) | (12,448 | ) | ||
| Changes in fair value on financial assets | 1,096 | — | — | |||||
| Operating loss | (178,554 | ) | € | (81,849 | ) | € | (22,932 | ) |
| Financial income | 14,399 | 3,694 | 1,250 | |||||
| Financial expense | (124 | ) | — | — | ||||
| Exchange gains/(losses) | 6,066 | 12,308 | (5,797 | ) | ||||
| Loss before taxes | (158,213 | ) | € | (65,847 | ) | € | (27,479 | ) |
| Income tax expense | (4,752 | ) | € | (794 | ) | € | (597 | ) |
| Loss for the year and total comprehensive loss | (162,965 | ) | € | (66,641 | ) | € | (28,076 | ) |
| Loss for the year and total comprehensive loss attributable to: | ||||||||
| Owners of the parent | (162,965 | ) | € | (66,641 | ) | € | (28,076 | ) |
| Weighted average number of shares outstanding | 38,619,121 | 33,419,356 | 24,609,536 | |||||
| Basic and diluted loss per share (in ) | (4.22 | ) | (1.99 | ) | (1.14 | ) |
All values are in Euros.
ARGENX SE
CONSOLIDATED STATEMENTOF CASH FLOWS
| Year Ended | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| December 31, | |||||||||
| (in thousands of €) | 2019 | 2018 | 2017 | ||||||
| CASH FLOWS (USED IN) / FROM OPERATING ACTIVITIES | |||||||||
| Operating result | € | (178,554 | ) | € | (81,849 | ) | € | (22,932 | ) |
| Adjustments for non-cash items | |||||||||
| Amortization of intangible assets | 38 | 19 | 10 | ||||||
| Depreciation of property, plant and equipment | 2,128 | 474 | 425 | ||||||
| Loss on disposal of fixed assets | — | — | 11 | ||||||
| Provisions for employee benefits | 57 | (18 | ) | 24 | |||||
| Expense recognized in respect of share-based payments | 39,552 | 19,183 | 4,268 | ||||||
| Fair value gains on financial assets at fair value through profit or loss | (1,096 | ) | — | — | |||||
| € | (137,875 | ) | € | (62,191 | ) | € | (18,195 | ) | |
| Movements in current assets/liabilities | |||||||||
| (Increase)/decrease in trade and other receivables | (22,965 | ) | (44 | ) | (122 | ) | |||
| (Increase)/decrease in other current assets | (5,170 | ) | (800 | ) | (1,093 | ) | |||
| Increase/(decrease) in trade and other payables | 47,995 | 21,784 | 3,094 | ||||||
| Increase/(decrease) in deferred revenue – current | 62,106 | (8,868 | ) | (11,501 | ) | ||||
| Movements in non-current assets/liabilities | |||||||||
| (Increase)/decrease in other non-current assets | (5,560 | ) | (1,720 | ) | (94 | ) | |||
| (Increase)/decrease in deferred revenue – non-current | 200,533 | (1,435 | ) | (8,635 | ) | ||||
| Cash flows (used in)/from operating activities | 139,064 | (53,274 | ) | (36,546 | ) | ||||
| Interest paid | (124 | ) | — | — | |||||
| Income taxes paid | (4,356 | ) | (565 | ) | — | ||||
| NET CASH FLOWS (USED IN) / FROM OPERATING ACTIVITIES | € | 134,584 | € | (53,839 | ) | € | (36,546 | ) | |
| CASH FLOWS (USED IN) / FROM INVESTING ACTIVITIES | |||||||||
| Purchase of intangible assets | (40,143 | ) | (62 | ) | (6 | ) | |||
| Purchase of property, plant and equipment | (1,604 | ) | (622 | ) | (345 | ) | |||
| (Increase)/decrease in financial assets – current | (708,060 | ) | (108,229 | ) | (162,076 | ) | |||
| Interest received | 5,469 | 1,371 | 375 | ||||||
| NET CASH FLOWS (USED IN) / FROM INVESTING ACTIVITIES | € | (744,338 | ) | € | (107,542 | ) | € | (162,052 | ) |
| CASH FLOWS (USED IN) / FROM FINANCING ACTIVITIES | |||||||||
| Principal elements of lease payments | (1,353 | ) | — | — | |||||
| Proceeds from issue of new shares, gross amount | 678,936 | 255,721 | 327,700 | ||||||
| Issue costs paid | (22,999 | ) | (14,655 | ) | (23,015 | ) | |||
| Exchange gain from currency conversion on proceeds from issue of new shares | — | 1,354 | — | ||||||
| Proceeds from exercise of stock options | 4,775 | 2,251 | 679 | ||||||
| NET CASH FLOWS (USED IN) / FROM FINANCING ACTIVITIES | € | 659,359 | € | 244,671 | € | 305,365 | |||
| NET INCREASE (DECREASE) IN CASH & CASH EQUIVALENTS | € | 49,605 | € | 83,290 | € | 106,767 | |||
| Cash and cash equivalents at the beginning of the period | € | 281,040 | € | 190,867 | € | 89,897 | |||
| Exchange gains/(losses) on cash & cash equivalents | € | 637 | € | 6,883 | € | (5,797 | ) | ||
| Cash and cash equivalents at the end of the period | € | 331,282 | € | 281,040 | € | 190,867 |
ARGENX SE
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
| Attributable<br> to owners of the parent | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (in<br> thousands of €) | Share<br><br> capital | Share<br><br> premium | Accumulated<br><br> losses | Other<br><br> reserves | Total<br><br> equity<br> attributable<br> to owners<br> of the<br> parent | Total<br><br> equity | ||||||||||
| Balance<br> at January 1, 2017 | € | 2,012 | € | 126,358 | € | (72,492 | ) | € | 7,496 | € | 63,374 | € | 63,374 | |||
| Total<br> comprehensive loss of the period | (28,076 | ) | (28,076 | ) | (28,076 | ) | ||||||||||
| Share-based<br> payment | 4,268 | 4,268 | 4,268 | |||||||||||||
| Issue<br> of share capital | 1,185 | 326,515 | 327,700 | 327,700 | ||||||||||||
| Transaction<br> costs for equity issue | (23,015 | ) | (23,015 | ) | (23,015 | ) | ||||||||||
| Exercise<br> of stock options | 19 | 660 | 679 | 679 | ||||||||||||
| Balance<br> year ended December 31, 2017 | € | 3,216 | € | 430,518 | € | (100,568 | ) | € | 11,764 | € | 344,931 | € | 344,931 | |||
| Adoption<br> of IFRS 15 (modified retrospective approach) | (2,395 | ) | (2,395 | ) | (2,395 | ) | ||||||||||
| Restated<br> total equity at January 1, 2018 | € | 3,216 | € | 430,518 | € | (102,962 | ) | € | 11,764 | € | 342,536 | € | 342,536 | |||
| Total<br> comprehensive loss of the period | (66,641 | ) | (66,641 | ) | (66,641 | ) | ||||||||||
| Share-based<br> payment | 19,183 | 19,183 | 19,183 | |||||||||||||
| Issue<br> of share capital | 347 | 255,374 | 255,721 | 255,721 | ||||||||||||
| Transaction<br> costs for equity issue | (14,655 | ) | (14,655 | ) | (14,655 | ) | ||||||||||
| Exercise<br> of stock options | 34 | 2,217 | 2,251 | 2,251 | ||||||||||||
| Balance year ended December 31, 2018 | € | 3,597 | € | 673,454 | **** | € | (169,603 | ) | € | 30,947 | € | 538,395 | **** | € | 538,395 | **** |
| Total<br> comprehensive loss of the period | (162,965 | ) | (162,965 | ) | (162,965 | ) | ||||||||||
| Share-based<br> payment | 39,552 | 39,552 | 39,552 | |||||||||||||
| Issue<br> of new shares | 637 | 678,299 | 678,936 | 678,936 | ||||||||||||
| Transaction<br> costs for equity issue | (22,999 | ) | (22,999 | ) | (22,999 | ) | ||||||||||
| Accounting<br> treatment of the share subscription agreement | (24,948 | ) | (24,948 | ) | (24,948 | ) | ||||||||||
| Exercise<br> of stock options | 42 | 4,733 | 4,775 | 4,775 | ||||||||||||
| Balance<br> year ended December 31, 2019 | € | 4,276 | € | 1,308,539 | € | (332,568 | ) | € | 70,499 | € | 1,050,746 | € | 1,050,746 |